

**Docket File Information**  
**SAFETY INSPECTION REPORT  
AND COMPLIANCE INSPECTION**

1. LICENSEE <b>Porter Valparaiso Hospital Campus</b> REPORT <b>2007-001</b>		2. NRC/REGIONAL OFFICE <b>Region III</b> <b>2443 Warrenville Road</b> <b>Lisle, IL 60532</b>	
3. DOCKET NUMBER(S) <b>030-12150</b>		4. LICENSE NUMBER(S) <b>13-17073-01</b>	5. DATE(S) OF INSPECTION <b>August 20, 2007</b>
6. INSPECTION PROCEDURES <b>87131/87132</b>		7. INSPECTION FOCUS AREAS <b>03.01-03.07</b>	
<b>SUPPLEMENTAL INSPECTION INFORMATION</b>			
1. PROGRAM <b>2120</b>	2. PRIORITY <b>G3</b>	3. LICENSEE CONTACT <b>James Forde, M.D., RSO</b>	4. TELEPHONE NUMBER
<input checked="" type="checkbox"/> Main Office Inspection	<input type="checkbox"/> Field	<input type="checkbox"/> Temporary Job Site	Next Inspection Date: <b>August 2010</b>

**PROGRAM SCOPE**

This 300 bed medical institution performs about 400 diagnostic nuclear medicine procedures monthly. Licensed material is obtained from an area pharmacy in the form of unit doses. Use of Moly/Tc generators has been discontinued. Currently five full-time and one part-time technologists are involved with program activities.

The licensee performs approximately 6 iodine-131 HTT's monthly and 12 treatments for ablation are performed annually, both in capsule form. No other radiopharmaceutical treatments are performed. A medical consultant is available quarterly to audit the existing program which adequately oversees licensed activities.

The licensee's brachytherapy program consists mainly of five iodine-125 ultrasound guided prostate implants quarterly and about one cesium-137 implant annually. The last cesium-137 implant was performed in August 2006. The licensee no longer performs Intervascular brachytherapy (IVB) procedures.

**Performance Observations**

Interviews conducted with available staff revealed an adequate level of understanding of emergency and material handling procedures and techniques. Daily dose calibrator checks, package surveys and wipes, area surveys, and patient injections were demonstrated or described with no problems noted. Interviews conducted along with representative record reviews of the licensee's quality management program revealed adequate responses and proper documentation for both radiopharmaceutical and brachytherapy modalities.

The licensee exchanges personal dosimetry monthly. A record review of dosimetry readings for 2006 revealed maximum whole body and extremity readings of 618 mrem and 3440 mrem respectively. YTD 2007 whole-body and extremity readings revealed 256 mrem and 1270 mrem respectively. Personnel dosimetry for the brachytherapy program revealed "M" extremity and 2 mrem whole-body for 2006 and "M" extremity and 1.0 mrem whole-body for 2007.

Overall, licensed material was observed adequately secured and/or under surveillance during the review and was not readily accessible to members of the general public. Independent measurements taken in the hot lab area revealed 0.05mr/hr behind the lead shield and essentially background (0.02mr/hr) in restricted and unrestricted areas.

*[Handwritten Signature]*  
8.30.07